People taking Ozempic and Wegovy may be at increased risk of developing a debilitating eye condition that can cause irreversible vision loss, a study published Wednesday in JAMA Ophthalmology finds
The table below shows common examples
The SURMOUNT-1 trial found that participants achieved average weight reductions of 16%, 19.5%, and about 21% on the 5 mg, 10 mg, and 15 mg doses, respectively, over 72 weeks
The weight-loss indication carries a markedly higher risk than diabetes treatment alone, because diabetes patients often receive lower doses and lose less weight
It came properly packaged and with everything necessary for use, along with the instructions
Holman, UKPDS Study Group: risk factors for renal dysfunction in type 2 diabetes: U.K